Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures

被引:8
作者
Campo, RE
Moreno, JN
Suarez, G
Miller, N
Kolber, MA
Holder, DJ
Shivaprakash, M
DeAngelis, DM
Wright, JL
Schleif, WA
机构
[1] Univ Miami, Sch Med, Div Infect Dis, Miami, FL 33136 USA
[2] Univ Miami, Sch Med, Dept Pathol, Miami, FL 33136 USA
[3] Merck Res Labs, Dept Biometr Res, West Point, PA USA
[4] Merck Res Labs, Dept Virol Vaccine Res, West Point, PA USA
关键词
indinavir; ritonavir; salvage therapy; genotypic resistance; phenotypic resistance; adherence; increased drug exposure;
D O I
10.1097/00002030-200309050-00012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To assess responses to indinavir (IDV)-ritonavir (RTV)-based regimens among HIV-1 infected patients with prior failure of protease inhibitors, and to assess the effects of adherence to therapy and pre-existing genotypic and phenotypic resistance on this response. Methods: Twenty-eight patients initiating salvage regimens with IDV-RTV (800 mg and 200 mg twice daily, respectively) plus one or more reverse transcriptase inhibitor (RTI) were identified retrospectively. Genotypic and phenotypic susceptibilities to multiple antiretroviral agents were determined on viral samples collected at initiation of the salvage regimens, and adherence to therapy was determined through patient self-reporting. Response to therapy (viral RNA less than or equal to 400 copies/ml) was assessed at the end of and beyond 6 months of follow-up. Results: Based on responses measured in the first 6 months of follow-up, 16 responders and 12 non-responders were identified without differences in baseline demographic factors, laboratory parameters, extent of prior antiretroviral therapy, or characteristics of the RTI components of the new IDV-RTV-based regimens. Adequate adherence was associated with virologic responses (P = 0.005). There were trends for genotypic and phenotypic resistance to be associated with adequate adherence, and, surprisingly, phenotypic resistance to IDV was associated with virologic response rather than with therapeutic failure (P = 0.02). Beyond 6 months of follow-up (mean follow-up 69 weeks), adequate adherence was still associated with virologic response (P = 0.001), but genotypic or phenotypic resistance to IDV were not associated with therapeutic failure. Conclusions: These results suggest that IDV-RTV-based regimens may be able to overcome IDV resistance. This underscores the importance of drug adherence, potency, and exposure in determining virologic responses to antiretroviral therapy. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:1933 / 1939
页数:7
相关论文
共 46 条
[1]   Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population [J].
Bangsberg, DR ;
Hecht, FM ;
Charlebois, ED ;
Zolopa, AR ;
Holodniy, M ;
Sheiner, L ;
Bamberger, JD ;
Chesney, MA ;
Moss, A .
AIDS, 2000, 14 (04) :357-366
[2]   A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy [J].
Baxter, JD ;
Mayers, DL ;
Wentworth, DN ;
Neaton, JD ;
Hoover, ML ;
Winters, MA ;
Mannheimer, SB ;
Thompson, MA ;
Abrams, DI ;
Brizz, BJ ;
Ioannidis, JPA ;
Merigan, TC .
AIDS, 2000, 14 (09) :F83-F93
[3]   Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients [J].
Benson, CA ;
Deeks, SG ;
Brun, SC ;
Gulick, RM ;
Eron, JJ ;
Kessler, HA ;
Murphy, RL ;
Hicks, C ;
King, M ;
Wheeler, D ;
Feinberg, J ;
Stryker, R ;
Sax, PE ;
Riddler, S ;
Thompson, M ;
Real, K ;
Hsu, A ;
Kempf, D ;
Japour, AJ ;
Sun, E .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (05) :599-607
[4]   Resistance to human immunodeficiency virus type 1 protease inhibitors [J].
Boden, D ;
Markowitz, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) :2775-2783
[5]   Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration [J].
Buss, N ;
Snell, P ;
Bock, J ;
Hsu, A ;
Jorga, K .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (03) :255-264
[6]  
Cabana M, 1999, J MED VIROL, V59, P480, DOI 10.1002/(SICI)1096-9071(199912)59:4&lt
[7]  
480::AID-JMV10&gt
[8]  
3.0.CO
[9]  
2-8
[10]   Failure of a ritonavir plus saquinavir-based rescue regimen precludes the use of protease inhibitors [J].
Casado, JL ;
Dronda, F ;
Hertogs, K ;
Antela, A ;
Moreno, S .
AIDS, 2000, 14 (04) :466-468